Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. - Wikidata - wikimedia - TriplyDB

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.

http://www.wikidata.org/entity/Q34316944

about

Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications The Role of Galectin-3 in the Kidneys State of the Art: Newer biomarkers in heart failure The fibrosis-cell death axis in heart failure Effects of anesthesia on conventional and speckle tracking echocardiographic parameters in a mouse model of pressure overload.Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study Galectin 3 and incident atrial fibrillation in the community.Developing therapies for heart failure with preserved ejection fraction: current state and future directions Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation.Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure Emerging biomarkers in heart failure and cardiac cachexia Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis.Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Cardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscle and Liver Fibrosis in Mice Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion.Plasma galectin 3 and heart failure risk in the Physicians' Health Study.Galectin-3: a novel biomarker for the prognosis of heart failure.Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction.Developments in the management of Chagas cardiomyopathy.Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities.Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes Cardiac oxidative stress in a mouse model of neutral lipid storage disease.Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging.Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway Role for Galectin-3 in Calcific Aortic Valve Stenosis.Serial galectin-3 and future cardiovascular disease in the general population.

P2860

Q26749488-5811E94A-BE51-4870-B817-78902F5E9721 Q26752754-E8B9FF82-82A6-4530-A1F1-76D98A4682D8 Q27027899-C3515DE9-A382-479F-9AFE-C899F6C4AD9F Q28076570-E413F460-C070-4E4C-8FCD-39CF84CA117B Q30407804-F316E734-E43E-4628-B79F-78420E758060 Q30841381-B49A29D7-1D11-453C-9720-488536EDE868 Q31036336-98A7A65E-F8BD-4EF9-A1AD-A156545DA47B Q33555143-BEFE218F-9A42-4788-9DC6-B5EBDC1D8486 Q33639223-DCF16BEA-A70B-4284-8D1A-5004F78FAF93 Q33643393-61E0D9F9-88AA-4999-9710-FA1832D02AE1 Q33754895-A004C513-1951-4B50-A7B0-44A5157C4B82 Q33754984-5CE351D8-7F1D-4619-8D6A-1481527BE4E4 Q33897327-BF69CB7D-6A8F-4B71-B14D-EA6A5A3A1750 Q34472413-9F768114-B4B4-43A2-ABD1-65ABCB07324B Q34836097-42C3D130-FE70-4B35-B298-159287FA0B08 Q35026202-34F5AA85-5069-449C-B52F-C68AA3C6FA72 Q35070734-C7F382C7-5C6B-492B-A0E3-A1A206C13586 Q35108388-8202CCD2-6303-4BFA-81A9-7A77688A05EF Q35191679-84CA904D-34CC-402E-AAD1-4F7AE4322B0E Q35204841-60B71F9C-9649-408D-9721-725132D129FD Q35206146-45D0CB11-0DE5-4D32-9A5B-54438E4452EB Q35393885-8D2C855F-42FF-49FB-94D5-FE7BED2CADE0 Q35432573-66E5C011-87C1-44B2-B4AF-F421F05C7763 Q35807149-444602A3-41BE-476E-A13E-0F36A5A70E17 Q36052222-0139B60B-CC90-4A4F-9784-97F71818D2E4 Q36085814-560A60C8-2A36-442C-9026-57A410387358 Q36217826-34E03525-12C7-442F-9077-2E1AAB8657F6 Q36283028-2646B2D9-CB71-40CF-A18E-CB698CA4306F Q36385583-73693C3E-226F-4D7E-B998-099ABC5963B4 Q36627699-42E87ECC-9DAA-498C-8608-DF936D2D2B42 Q36737035-E55D8A55-3800-45A2-BEA2-F87C15248046 Q36885706-B1FA169B-2795-408E-8C2A-FBCBEDE89BCA Q37096257-AFE03D4B-9EC9-4EC2-B1DB-AACA5AAA7681 Q37125501-4063F20A-1FC0-4462-AECF-3B30E2D63CBF Q37164851-CDEA6DF0-833F-4C0B-A54C-B8D4B2302B78 Q37226723-FD58720B-FF88-4EB5-8F55-2CC482581DEE Q37504087-8BD37715-ED01-4257-A21F-9818129391EC Q37516514-4AE55A1D-22C1-4EA6-B6FC-0460AE9C0697 Q37556207-F21596DB-0A41-4DD1-812D-829B2BEAB9B6 Q37580709-3F47EDC3-7721-4F80-966B-FF27F4DFDEFF

P2860

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.

http://www.wikidata.org/entity/Q34316944

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@ast

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@en

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@nl

type

label

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@ast

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@en

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@nl

prefLabel

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@ast

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@en

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@nl

P1433

Q34316944-EB2D2B94-A3D7-41FD-A4CF-25FFCFB81593

P1476

Q34316944-9A3DFF84-3F3C-40DF-A01E-B1B6AE989CFF

P2093

Q34316944-1F25B79B-0B61-4865-A71F-4CA204F074AE

Q34316944-2817EC63-097C-4EE4-A5E3-A201382F1FBF

Q34316944-3C835CA2-B766-4BEB-902F-FBEC70E58068

Q34316944-99060EA4-B0C8-40AA-91B8-B62E5CD41EF2

Q34316944-A34C4FE1-8F26-4110-92C9-0C791AFF24C7

Q34316944-A54C6FD0-42C4-479F-AE3B-B112382CFE4B

Q34316944-A98D6F81-9044-4422-95FC-B9FD1F3BD55F

Q34316944-B2FD88D6-D4ED-4C50-B98A-3B330B87E9CF

Q34316944-B992FC79-C6D4-4F82-A6E6-3D0E84F7DF55

Q34316944-CAF581A2-809E-40BA-8BCA-2264D173D61C

P304

Q34316944-4BE52BAB-EDFE-4A99-AFC9-C285AFE95781

P31

Q34316944-C66515D5-3E0A-45E8-BC8B-D5FA08EA7D61

P356

Q34316944-42C83B07-F983-461A-B70D-E86FC749C6D2

P433

Q34316944-BD8EDCC0-E57B-435D-86CE-3A8517A69215

P478

Q34316944-702B001B-73EF-492D-9BA1-4554927FC22F

P50

Q34316944-1C2F85FC-6814-44AC-8265-82C26037B019

Q34316944-9916F8E1-9CDB-482A-887B-C746BF3589AA

Q34316944-F7704195-4682-4629-83AC-19237842DAEF

Q34316944-FF4FADA5-6CBC-4EC7-8E1D-025F625EACBC

P577

Q34316944-37951B7B-FFCD-4FDF-A986-D9311AAF6651

P698

Q34316944-A903A848-1A6B-45DC-B2E6-1608842965AB

P921

Q34316944-BDF7D377-3AA1-48FC-8483-8C2177DD3CA6

P356

CIRCHEARTFAILURE.112.971168

P1433

Circulation: Heart Failure

P1476

Genetic and pharmacological in ...... with myocardial fibrogenesis.

@en

P2093

Bahram Sanjabi

http://www.w3.org/2001/XMLSchema#string

Eelke M Bos

http://www.w3.org/2001/XMLSchema#string

Herman H W Silljé

http://www.w3.org/2001/XMLSchema#string

Irwin J Goldstein

http://www.w3.org/2001/XMLSchema#string

Jasper A Koerts

http://www.w3.org/2001/XMLSchema#string

Lili Yu

http://www.w3.org/2001/XMLSchema#string

Maxi Meissner

http://www.w3.org/2001/XMLSchema#string

Pim van der Harst

http://www.w3.org/2001/XMLSchema#string

Rudolf A de Boer

http://www.w3.org/2001/XMLSchema#string

Ruud A Bank

http://www.w3.org/2001/XMLSchema#string

P304

107-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCHEARTFAILURE.112.971168

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Pim van der Harst

Dirk J van Veldhuisen

P577

2012-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23230309

http://www.w3.org/2001/XMLSchema#string

P921